Abstract
After being recognized as a syndrome, Willis–Ekbom disease (WED) had been essentially ignored for three centuries until the excellent work of Ekbom in the mid-twentieth-century, carefully describing his case series. Shortly thereafter, attention to disorders disturbing sleep increased with advent of the discipline of sleep medicine. The discovery of periodic leg movements in sleep as a common feature of WED and then the serendipitous discovery of dopaminergic treatment both produced increased interest and attention to WED as a neurological disease. It was then appreciated that as Ekbom previously reported: This condition is so common that every physician is almost certain to see these patients in their practice. This has led to a rapid development of measurement instruments, diagnostic standards, approved treatments, and better understanding of the iron and genetic factors of WED. Much more could be considered about the history of assessments regarding social costs, quality of life, sleep, and multiple biological factors in the disease. Suffice it to note that this disease has rapidly progressed in the last half century from one unknown and untreatable to one with good treatment options and clear directions for biologically based improvements in the future.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Willis T. The London practice of physick. London: Bassett and Crooke; 1685.
Allen RP, Stillman P, Myers AJ. Physician-diagnosed restless legs syndrome in a large sample of primary medical care patients in western Europe: prevalence and characteristics. Sleep Med. 2010;11:31–7.
Allen RP, Bharmal M, Calloway M. Prevalence and disease burden of primary restless legs syndrome: results of a general population survey in the United States. Mov Disord. 2011;26:114–20.
Willis T. De Animae Brutorum. London: Wells and Scott; 1672.
Wittmaack T. Pathologie und Therapie der Sensibilitäts neurosen. Liepzig: Schäfer; 1861.
Beard G. A practical treatis on nervous exhaustion. New York: William Wood; 1880.
Ekbom KA. Asthenia crurum paraesthetica (“irritable legs”). Acta Medica Scandinavica. 1944;118(1–3):197–209.
Ekbom KA. Restless legs. Stockholm: Ivar Haeggströms; 1945.
Mussio-Fournier JC, Rawak F. Familiäres Auftreten von Pruritus, Utikaria und parästhetischer Hyperkinese der unteren Extremitäten. Confinia Neurol. 1940;3:110–4.
Allison FG. Obscure pains in the chest, back or limbs. Can Med Assoc J. 1943;48:36–9.
Symonds CP. Nocturnal myoclonus. J Neurol Neurosurg Psychiatr. 1953;16:166.
Lugaresi E, Coccagna G, Berti Ceroni G, Ambrosetto C. Restless legs syndrome and nocturnal myoclonus. In: Gastaut H, Lugaresi E, Berti Ceroni G, editors. The abnormalites of sleep in man. Bologna: Aulo Gaggi Editore; 1968. 285–94.
Montplaisir J, Boucher S, Poirier G, Lavigne G, Lapierre O, Lesperance P. Clinical, polysomnographic, and genetic characteristics of restless legs syndrome: a study of 133 patients diagnosed with new standard criteria. Mov Disord. 1997;12:61–5.
Montplaisir J, Michaud M, Denesle R, Gosselin A. Periodic leg movements are not more prevalent in insomnia or hypersomnia but are specifically associated with sleep disorders involving a dopaminergic impairment. Sleep Med. 2000;1:163–7.
Pennestri MH, Whittom S, Adam B, Petit D, Carrier J, Montplaisir J. PLMS and PLMW in healthy subjects as a function of age: prevalence and interval distribution. Sleep. 2006;29:1183–7.
ASDA. International classification of sleep disorders, revised: Diagnostic and coding manual. Rochester, Minnesota: American Sleep Disorders Association; 1997.
Allen RP, Barker PB, Horska A, Earley CJ. Thalamic glutamate/glutamine in restless legs syndrome: increased and related to disturbed sleep. Neurology. 2013;80:2028–34.
Walters AS, Hening WA, Chokroverty S. Frequent occurrence of myoclonus while awake and at rest, body rocking and marching in place in a subpopulation of patients with restless legs syndrome. Acta Neurol Scand. 1988;77:418–21.
Walters AS, Aldrich MA, Allen RP, Ancoli-Israel S, Buchholz D, Chockroverty S, et al. Toward a better definition of the restless legs syndrome. Mov Disord. 1995;10:634–42.
Allen RP, Picchietti D, Hening WA, Trenkwalder C, Walters AS, Montplaisir J. Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health. Sleep Med. 2003;4:101–19.
Hening WA, Allen RP, Washburn M, Lesage S, Earley C. The four diagnostic criteria for the restless legs syndrome are unable to exclude confounding conditions (“mimics”). Sleep Med. 2009;10:976–81.
Cho, Y.W., et al., Prevalence and clinical characteristics of restless legs syndrome in diabetic peripheral neuropathy: comparison with chronic osteoarthritis. Sleep Med, 2013; 14: 1387–92
Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walter AS, Winkelman JW, et al. Restless legs syndrome/Willis-Ekbom disease diagnostic criteria: updated International Restless Legs Syndrome Study Group (IRLSSG) consensus criteria history, rationale, description, and signifi cance. Sleep Med, 2014;15:860–73.
Walters AS, LeBrocq C, Dhar A, Hening W, Rosen R, Allen RP, et al. Validation of the International Restless Legs Syndrome Study Group rating scale for restless legs syndrome. Sleep Med. 2003;4:121–32.
Abetz L, Arbuckle R, Allen RP, Garcia-Borreguero D, Hening W, Walters AS, et al. The reliability, validity and responsiveness of the International Restless Legs Syndrome Study Group rating scale and subscales in a clinical-trial setting. Sleep Med. 2006;7:340–9.
Lavigne GJ, Montplaisir JY. Restless legs syndrome and sleep bruxism: prevalence and association among Canadians. Sleep. 1994;17:739–43.
Allen RP, Walters AS, Montplaisir J, Hening W, Myers A, Bell TJ, et al. Restless legs syndrome prevalence and impact: REST general population study. Arch Intern Med. 2005;165:1286–92.
Allen RP, Burchell BJ, MacDonald B, Hening WA, Earley CJ. Validation of the self-completed Cambridge-Hopkins questionnaire (CH-RLSq) for ascertainment of restless legs syndrome (RLS) in a population survey. Sleep Med. 2009;10:1097–100.
O’Keeffe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. Age Ageing. 1994;23:200–3.
O’Keeffe ST, Noel J, Lavan JN. Restless legs syndrome in the elderly. Postgrad Med J. 1993;69:701–3.
Allen RP, Barker PB, Wehrl F, Song HK, Earley CJ. MRI measurement of brain iron in patients with restless legs syndrome. Neurology. 2001;56:263–5.
Earley CJ, Barker PB, Horska A, Allen RP. MRI-determined regional brain iron concentrations in early- and late-onset restless legs syndrome. Sleep Med. 2006;7:459–61.
Schmidauer C, Sojer M, Seppi K, Stockner H, Hogl B, Biedermann B, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol. 2005;58:630–4.
Godau J, Klose U, Di Santo A, Schweitzer K, Berg D. Multiregional brain iron deficiency in restless legs syndrome. Mov Disord. 2008;23:1184–7.
Godau J, Manz A, Wevers AK, Gaenslen A, Berg D. Sonographic substantia nigra hypoechogenicity in polyneuropathy and restless legs syndrome. Mov Disord. 2009;24:133–7.
Godau J, Schweitzer KJ, Liepelt I, Gerloff C, Berg D. Substantia nigra hypoechogenicity: definition and findings in restless legs syndrome. Mov Disord. 2007;22:187–92.
Connor JR, Boyer PJ, Menzies SL, Dellinger B, Allen RP, Earley CJ. Neuropathological examination suggests impaired brain iron acquisition in restless legs syndrome. Neurology. 2003;61:304–9.
Stefansson H1, Rye DB, Hicks A, et al. A genetic risk factor for periodic limb movements in sleep. N Engl J Med. 2007 Aug 16;357(7):639-47.
Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, et al. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007;39:1000–6.
Hening WA, Walters A, Kavey N, Gidro-Frank S, Cote L, Fahn S. Dyskinesias while awake and periodic movements in sleep in restless legs syndrome: treatment with opioids. Neurology. 1986;36:1363–6.
Mitler MM, Browman CP, Menn SJ, Gujavarty K, Timms RM. Nocturnal myoclonus: Treatment efficacy of clonazepam and temazepam. Sleep. 1986;9:385–92.
Boghen D, Lamothe L, Elie R, Godbout R, Montplaisir J. The treatment of the restless legs syndrome with clonazepam: a prospective controlled study. Can J Neurol Sci. 1986;13:245–7.
Akpinar S. Treatment of restless legs syndrome with levodopa plus benserazide [letter]. Arch Neurol. 1982;39:739.
Kaplan PW, Allen RP, Buchholz DW, Walters JK. A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. Sleep. 1993;16:717–23.
Allen RP, Kaplan PW, Buchholz DW, Earley CJ, Walters JK. Double-blinded, placebo controlled comparison of high dose propoxyphene and moderate dose carbidopa/levodopa for treatment of periodic limb movements in sleep. Sleep Res. 1992;21:166.
Allen R, Early CJ, Hening WA, Walters AS, Wagner MI, Yaffee JB. Double-blind, placebo-controlled, multi-center evaluation of the restless legs syndrome treatment with pergolide (abstract). Sleep. 1998;21:142.
Montplaisir J, Nicolas A, Denesle R, Gomez-Mancilla B. Restless legs syndrome improved by pramipexole: a double-blind randomized trial. Neurology. 1999;52:938–43.
Freeman A, Rye D, Bliwise DL, Chakravorty S, Krulewicz S, Watts R. Ropinirole fo restless legs syndrome (RLS): an open-label and double-blind placebo-controlled study. Neurology. 2001;56:A5.
Allen RP, Earley CJ. Augmentation of the restless legs syndrome with carbidopa/levodopa. Sleep. 1996;19:205–13.
Silber MH, Girish M, Izurieta R. Pramipexole in the management of restless legs syndrome: an extended study. Sleep. 2003;26:819–21.
Winkelman JW, Johnston L. Augmentation and tolerance with long-term pramipexole treatment of restless legs syndrome (RLS). Sleep Med. 2004;5:9–14.
Inoue Y, Uchimura N, Kuroda K, Hirata K, Hattori N. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuropsychopharmacol Biol Psychiatry. 2012;36:251–7.
Lee DO, Ziman RB, Perkins AT, Poceta JS, Walters AS, Barrett RW, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7:282–92.
Walters AS, Ondo WG, Kushida CA, Becker PM, Ellenbogen AL, Canafax DM, et al. Gabapentin Enacarbil in Restless Legs Syndrome: A Phase 2b, 2-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Clin Neuropharmacol. 2009; 6:311-20.
Ondo WG. Methadone for refractory restless legs syndrome. Mov Disord. 2005;20:345–8.
Earley CJ, Connors JR, Allen RP. RLS patients have abnormally reduced CSF ferritin compared to normal controls. Neurology. 1999;52 (suppl 2):A111–A2.
Nordlander NB. Therapy in restless legs. Acta Med Scand. 1953;145:453–7.
Nordlander NB. Restless legs. Brit J Phys Med. 1954;17:160–2.
Unger EL, Earley CJ, Thomsen LL, Jones BC, Allen RP. Effects of IV iron isomaltoside-1000 treatment on regional brain iron status in an iron-deficient animal. Neuroscience. 2013;246:179–85.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Allen, R. (2015). History of Restless Legs Syndrome, Recently Named Willis–Ekbom Disease. In: Chokroverty, S., Billiard, M. (eds) Sleep Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-2089-1_30
Download citation
DOI: https://doi.org/10.1007/978-1-4939-2089-1_30
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-2088-4
Online ISBN: 978-1-4939-2089-1
eBook Packages: MedicineMedicine (R0)